Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps may ease rare movement disorder

NCT ID NCT06821256

Symptom relief Sponsor: University of Salerno Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a safe, non-invasive brain stimulation technique called tDCS to see if it can improve movement and balance in people with a rare neurological condition called Multiple System Atrophy - Cerebellar type (MSA-C). About 30 participants will receive either real or sham stimulation over several sessions. The goal is to measure changes in walking and coordination using motion sensors and clinical scales.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Multiple system atrophy cerebellar variant according with the Movemente Disorder Society criteria (Wenning et al 2022) * Ability to walk either indipendently or with a minimum support Exclusion Criteria: * Presence of electrical stimulators (for example, pacemaker, Deep Brain Stimulation, DBS) * Difficult in understanding Italian language * Presence of severe sensory deficits (for example, visual or hearing impairments) * History of drug abuse * History of severe psychiatric disorders * History of transient ischemic attacks * Cortical or sub-cortical vascular lesions * Seizures or severe heart problems and previous neurosurgical operations * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple system atrophy - cerebellar subtype (msa-C) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy, cerebellar type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy - cerebellar subtype (msa-C)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centro per le Malattie Neurodegenerative (CEMAND) Dipartimento di Medicina e chirurgia, Sezione Neuroscienze, Università di Salerno

    RECRUITING

    Salerno, Sa, 84131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.